# Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity

**Authors:** Lizao Zhang, Siqi Ren, Yuhui Li, Rongxi Chen, Ling Qiu, Yongmei Tan, Suling Chen, Huiqian Wu, Lianxi Mai, Xiao Tan, Xin Liu, Peisheng Liang, Shijia Kuang, Liansheng Wang, Jingkang Liu, Jintao Li, Yanyan Li, Qiuping Xu, Yongzhi Su, Yuehai Luo, Binyan Wu, Zijing Huang, Haotian Cao, Qunxing Li, Jinsong Li, Tianjun Lan

PMC · DOI: 10.1002/advs.202509340 · Advanced Science · 2025-11-27

## TL;DR

Retinoic acid can transform mast cells into a proinflammatory state, boosting antitumor immunity and improving cancer outcomes.

## Contribution

The study identifies a proinflammatory mast cell subset and reveals how retinoic acid signaling reprograms these cells to enhance antitumor immunity.

## Key findings

- Retinoic acid signaling through RARα promotes proinflammatory mast cell polarization.
- Proinflammatory mast cells are associated with improved clinical outcomes in multiple cancer types.
- RA–RARα–CIITA signaling enhances MHC-II expression and T cell activation in mast cells.

## Abstract

Mast cells play complex and context‐dependent roles within the tumor microenvironment, yet their molecular characteristics and functional diversity across human cancers remain poorly defined. In this study, single‐cell RNA sequencing and spatial transcriptomics data are integrated to comprehensively map the transcriptional and spatial heterogeneity of mast cells across ten cancer types. A distinct proinflammatory mast cell (PMC) population is identified, characterized by strong antigen‐presenting features and immune‐activating potential. Mechanistic analyses show that retinoic acid (RA) signaling drives the polarization of PMCs through activation of RARα, which promotes CIITA‐mediated MHC‐II expression, CXCL16 secretion, and T cell recruitment and activation. Across multiple cancer types, tumors with higher PMC abundance are associated with more favorable clinical outcomes. These findings reveal the pivotal role of RA–RARα–CIITA signaling in mast cell reprogramming and suggest that pharmacologic induction of proinflammatory mast cells may represent a promising approach to enhance antitumor immunity.

Proinflammatory mast cells represent an MHC‐IIhigh, cytokine‐producing mast cell subset associated with improved survival and enhanced responses to anti‐PD‐1 therapy. Retinoic acid drives their polarization, enabling antigen uptake and presentation, and T cell recruitment and activation, collectively promoting adaptive anti‐tumor immunity.

## Linked entities

- **Genes:** RARA (retinoic acid receptor alpha) [NCBI Gene 5914], CIITA (class II major histocompatibility complex transactivator) [NCBI Gene 4261]
- **Proteins:** H2 (histocompatibility-2, MHC), CXCL16 (C-X-C motif chemokine ligand 16)
- **Chemicals:** retinoic acid (PubChem CID 444795)

## Full-text entities

- **Genes:** RARA (retinoic acid receptor alpha) [NCBI Gene 5914] {aka NR1B1, RAR, RARalpha}, CIITA (class II major histocompatibility complex transactivator) [NCBI Gene 4261] {aka C2TA, CIITAIV, MHC2D1, MHC2TA, NLRA}, CXCL16 (C-X-C motif chemokine ligand 16) [NCBI Gene 58191] {aka CXCLG16, SR-PSOX, SRPSOX}
- **Diseases:** cancer (MESH:D009369)
- **Chemicals:** RA (MESH:D014212)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12866796/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12866796/full.md

## References

95 references — full list in the complete paper: https://tomesphere.com/paper/PMC12866796/full.md

---
Source: https://tomesphere.com/paper/PMC12866796